Program
DW1026C2
A development code.
Its studies are mostly in Diabetes Mellitus, Type 2, led by Daewon Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daewon Pharmaceutical | 10 open or running | phase 3since Jul 13, 2025 | Jul 13, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 13, 2025First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT07076056 · 230 enrolled · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07076056Diabetes Mellitus, Type 2 · South Korea | 3 | Completed | Dec 4, 2023 | 230 |
How it is read
Names in the registry
- “DW1026C2”, 1 entry
Codes read as this program: DW1026C2.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.